tamibarotene has been researched along with sulfasalazine in 1 studies
| Studies (tamibarotene) | Trials (tamibarotene) | Recent Studies (post-2010) (tamibarotene) | Studies (sulfasalazine) | Trials (sulfasalazine) | Recent Studies (post-2010) (sulfasalazine) |
|---|---|---|---|---|---|
| 198 | 10 | 105 | 4,437 | 585 | 938 |
| Protein | Taxonomy | tamibarotene (IC50) | sulfasalazine (IC50) |
|---|---|---|---|
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 1.5 | |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 3 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 3.04 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.49 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 6.332 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 9.6 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.46 | |
| Cystine/glutamate transporter | Homo sapiens (human) | 0.16 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.56 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chakrabarti, KS; Choi, J; de Groot, BL; Gapsys, V; Griesinger, C; Ha, JH; Jee, JG; Kim, BR; Kim, M; Lee, D; Lee, KO; Ryu, KS | 1 |
1 other study(ies) available for tamibarotene and sulfasalazine
| Article | Year |
|---|---|
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
Topics: Catalytic Domain; Crystallography, X-Ray; Drug Repositioning; Enzyme Inhibitors; Humans; Molecular Dynamics Simulation; Nuclear Magnetic Resonance, Biomolecular; Oxidoreductases Acting on CH-CH Group Donors; Protein Binding; Small Molecule Libraries; Thermodynamics; United States; United States Food and Drug Administration | 2022 |